Bispecific antibodies in multiple myeloma: present and future
G Lancman, DL Sastow, HJ Cho, S Jagannath… - Blood cancer …, 2021 - AACR
Despite many recent advances in therapy, there is still no plateau in overall survival curves
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …
Bispecific T‐cell engagers for treatment of multiple myeloma
Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly
engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs …
engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs …
Bi-specific and tri-specific NK cell engagers: the new avenue of targeted NK cell immunotherapy
SK Phung, JS Miller, M Felices - Molecular Diagnosis & Therapy, 2021 - Springer
Natural killer (NK) cell-mediated cancer immunotherapy has grown significantly over the
past two decades. More recently, multi-specific engagers have been developed as cancer …
past two decades. More recently, multi-specific engagers have been developed as cancer …
NK cell phenotype is associated with response and resistance to daratumumab in relapsed/refractory multiple myeloma
CPM Verkleij, KA Frerichs, MEC Broekmans… - …, 2023 - journals.lww.com
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM).
Natural killer (NK) cells play an important role during daratumumab therapy by mediating …
Natural killer (NK) cells play an important role during daratumumab therapy by mediating …
Immunotherapy of multiple myeloma: promise and challenges
HN Abramson - ImmunoTargets and Therapy, 2021 - Taylor & Francis
Whereas the treatment of MM was dependent solely on alkylating agents and corticosteroids
during the prior three decades, the landscape of therapeutic measures to treat the disease …
during the prior three decades, the landscape of therapeutic measures to treat the disease …
Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA/CD16A bispecific tetravalent antibody for the treatment …
H Cai, S Kakiuchi-Kiyota, R Hendricks, S Zhong, L Liu… - The AAPS Journal, 2022 - Springer
Abstract RO7297089, an anti-B-cell maturation antigen (BCMA)/CD16A bispecific tetravalent
antibody, is being developed as a multiple myeloma (MM) therapeutic. This study …
antibody, is being developed as a multiple myeloma (MM) therapeutic. This study …
The evolving status of immunotherapies in multiple myeloma: The future role of bispecific antibodies
D Swan, D Routledge, S Harrison - British Journal of …, 2022 - Wiley Online Library
Treatment outcomes in multiple myeloma (MM) have improved dramatically over the past 10
years. However, patients with high‐risk disease such as those with Stage III disease by the …
years. However, patients with high‐risk disease such as those with Stage III disease by the …
Design, Engineering, and Characterization of a Bispecific Killer Cell Engager With High Affinity and Specificity Toward CD16a Receptor on Natural Killer Cells for …
SK Nikkhoi - 2023 - search.proquest.com
Design, Engineering, and Characterization of a Bispecific Killer Cell Engager With High
Affinity and Specificity Toward CD16a Receptor on Natural Killer Cells for Cancer …
Affinity and Specificity Toward CD16a Receptor on Natural Killer Cells for Cancer …
Design, engineering, and characterization of a bispecific killer cell engager with high affinity and specificity toward CD16a receptor on natural killer cells for cancer …
S Khoshtinat Nikkhoi - 2023 - rucore.libraries.rutgers.edu
DESIGN, ENGINEERING, AND CHARACTERIZATION OF A BISPECIFIC KILLER CELL ENGAGER
WITH HIGH AFFINITY AND SPECIFICITY TOWARD CD16a RE Page 1 DESIGN, ENGINEERING …
WITH HIGH AFFINITY AND SPECIFICITY TOWARD CD16a RE Page 1 DESIGN, ENGINEERING …